CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 132 enrolled
Drug / intervention
Dakin's solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02369835
NCT02369835Phase 3Completed

A Randomized Study of Topical Dilute Hypochlorite (Modified Dakin's Solution) Treatment for the Prevention of Radiation Dermatitis in Head and Neck Cancer

Stanford University·interventional·Posted Feb 24, 2015·Updated Jan 30, 2024

In Brief

A Phase 3 clinical trial evaluating Dakin's solution and Placebo for Head and Neck Carcinoma and Radiation-Induced Dermatitis. Completed, enrolled 132 participants across 2 sites.

Detailed Summary

This randomized phase 3 trial studies how well modified Dakin's solution works in reducing radiation-induced dermatitis, a common skin reaction to radiation therapy, in patients with head and neck cancer undergoing radiation therapy. Modified Dakin's solution may reduce inflammation in the body, which may prevent or reduce dermatitis after radiation therapy. Radiation therapy in this study is regulatory medical care based on the patient's needs and the radiation oncologist's judgment. It is not possible nor necessary to explicitly define the dose or duration of treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 24, 2015
Enrollment StartMay 1, 2015
Primary CompletionJul 18, 2018
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 11.4 years ago

Interventions

Dakin's solutiondrug

Apply modified Dakin's solution (0.005 to 0.01%) topically

Placeboother

Applied topically